We are amazed and inspired by the tremendous success of the Clarapath team. This type of innovation will transform the delivery of care by improving quality, access and lowering cost. We’re excited to see the company introduce this breakthrough solution to the market. #robotics, #pathology, #healthcare #SeriesB
We are pleased to share the news of our recent $36 million Series B-1 funding round. With this latest round, Clarapath is poised to be the first US-based company to develop and deploy a new category of ground-breaking healthcare robotics, machine vision and digital automation tools, elevating the standard for hospitals and patients. Currently in the US, more than 12 million human and veterinary biopsies are performed each year, with millions more for biopharmaceutical drug safety. Today, a multi-prong crisis exists in laboratories that is driven by severe labor shortages, rising caseloads and an antiquated, manual process of preparing tissue samples. Led by Northwell Holdings, additional new strategic investors participated in the financing, including CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Health Ventures, bringing the company's total funding to $75 million. Eric Feinstein Matthew Claster Richard Mulry Michael Dowling Greg Sossaman Joaquin Garcia, MD Joe Moscola, PA-C, MBA Alain Borczuk Sami Yusuf, PharmD,MS,MBA Steven Lindseth David Eigen Hassan Dayekh Jessie A. Matthew O. Leavitt, MD Scott Lancaster, MD, MBA Blindspot Ventures Northwell Health acrewood holdings Lumea #healthcareventurefunding #healthcarerobotics #clarapath #histopathology #seriesB #pathology #innovation #laboratorymedicine #biopsy #machinevision #digitalautomation #veterinarymedicine #pharmaresearch #sectionstar https://lnkd.in/eEwX6s3K